Cortecs has launched its point-of-care diagnostic for osteoporosis,Osteosal, in the UK. The test measures Cortecs' proprietary CrossLaps marker, which indicates bone resorption when present in high levels. A result can be expected within minutes, says the firm.
Osteosal joins Cortecs' Helisal and Helisal One Step tests for Helicobacter pylori, which are already available. Launch of Osteosal to general practitioners is forecast for the spring of 1998.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze